14/02/2026
๐ ๐น๐ผ๐ป๐ด-๐ฎ๐ป๐๐ถ๐ฐ๐ถ๐ฝ๐ฎ๐๐ฒ๐ฑ ๐ฑ๐ถ๐๐ฝ๐ฟ๐ผ๐ฝ๐ผ๐ฟ๐๐ถ๐ผ๐ป๐ฎ๐น๐ถ๐๐ ๐ฎ๐ป๐ฎ๐น๐๐๐ถ๐ ๐ณ๐ผ๐ฟ ๐ฆ๐ผ๐น๐ฒ๐ป๐๐ถ๐ฎ (๐ณ๐ฟ๐๐ป๐ฒ๐๐ฒ๐๐บ๐ฎ๐ฏ) ๐ต๐ฎ๐ ๐ท๐๐๐ ๐ฏ๐ฒ๐ฒ๐ป ๐ฝ๐๐ฏ๐น๐ถ๐๐ต๐ฒ๐ฑ in the Journal of Veterinary Internal Medicine (JVIM).
Almost exactly one year ago, a highly controversial disproportionality analysis examining ๐๐ถ๐ฏ๐ฟ๐ฒ๐น๐ฎ (๐ฏ๐ฒ๐ฑ๐ถ๐ป๐๐ฒ๐๐บ๐ฎ๐ฏ) was published, drawing debates within the veterinary community.
This new study performed a disproportionality analysis using data from the U.S. Food and Drug Administration (FDA) Animal Drug Adverse Event (ADAE) database, reviewing reports submitted between January 2022 and December 2024. Last yearโs Librela analysis in dogs used the European Medicines Agencyโs EudraVigilance veterinary database and specifically focused on musculoskeletal adverse events. In contrast, the Solensia study conducted a broad, system-wide evaluation across multiple organ systems.
From over 33,000 feline adverse event reports in the database, 5,248 were associated with frunevetmab. Using four independent statistical signal detection methods, the authors identified 19 adverse event terms that met disproportionality criteria. ๐ง๐ต๐ฒ ๐บ๐ผ๐๐ ๐ฝ๐ฟ๐ผ๐บ๐ถ๐ป๐ฒ๐ป๐ ๐ฝ๐ฎ๐๐๐ฒ๐ฟ๐ป ๐๐ฎ๐ ๐ฑ๐ฒ๐ฟ๐บ๐ฎ๐๐ผ๐น๐ผ๐ด๐ถ๐ฐ: ๐๐ธ๐ถ๐ป ๐๐น๐ฐ๐ฒ๐ฟ๐ฎ๐๐ถ๐ผ๐ป, ๐ฑ๐ฒ๐ฟ๐บ๐ฎ๐๐ถ๐๐ถ๐, ๐ฎ๐น๐ผ๐ฝ๐ฒ๐ฐ๐ถ๐ฎ, ๐ฝ๐ฟ๐๐ฟ๐ถ๐๐๐, ๐๐ป๐๐ฝ๐ฒ๐ฐ๐ถ๐ณ๐ถ๐ฒ๐ฑ ๐๐ธ๐ถ๐ป ๐ฑ๐ถ๐๐ผ๐ฟ๐ฑ๐ฒ๐ฟ๐, ๐ฎ๐ป๐ฑ ๐ถ๐ป๐ท๐ฒ๐ฐ๐๐ถ๐ผ๐ป-๐๐ถ๐๐ฒ ๐ฝ๐ฎ๐ถ๐ป ๐๐ต๐ผ๐๐ฒ๐ฑ ๐๐ต๐ฒ ๐๐๐ฟ๐ผ๐ป๐ด๐ฒ๐๐ ๐ฎ๐ป๐ฑ ๐บ๐ผ๐๐ ๐ฐ๐ผ๐ป๐๐ถ๐๐๐ฒ๐ป๐ ๐๐ถ๐ด๐ป๐ฎ๐น๐ ๐ฟ๐ฒ๐น๐ฎ๐๐ถ๐๐ฒ ๐๐ผ ๐ผ๐๐ต๐ฒ๐ฟ ๐ฑ๐ฟ๐๐ด๐ ๐ถ๐ป ๐ฐ๐ฎ๐๐.
๐๐ป ๐ฎ๐ฑ๐ฑ๐ถ๐๐ถ๐ผ๐ป, ๐๐ฒ๐๐ฒ๐ฟ๐ฎ๐น ๐ป๐ฒ๐๐ฟ๐ผ๐น๐ผ๐ด๐ถ๐ฐ ๐ฎ๐ป๐ฑ ๐บ๐๐๐ฐ๐๐น๐ผ๐๐ธ๐ฒ๐น๐ฒ๐๐ฎ๐น ๐๐ฒ๐ฟ๐บ๐ โ ๐ถ๐ป๐ฐ๐น๐๐ฑ๐ถ๐ป๐ด ๐ฝ๐ฎ๐ฟ๐ฒ๐๐ถ๐, ๐ฝ๐ฟ๐ผ๐ฝ๐ฟ๐ถ๐ผ๐ฐ๐ฒ๐ฝ๐๐ถ๐๐ฒ ๐ฎ๐ฏ๐ป๐ผ๐ฟ๐บ๐ฎ๐น๐ถ๐๐ถ๐ฒ๐, ๐ฎ๐ป๐ฑ ๐ฎ๐ฟ๐๐ต๐ฟ๐ถ๐๐ถ๐ โ ๐ฎ๐น๐๐ผ ๐ฑ๐ฒ๐บ๐ผ๐ป๐๐๐ฟ๐ฎ๐๐ฒ๐ฑ ๐ฒ๐น๐ฒ๐๐ฎ๐๐ฒ๐ฑ ๐ฟ๐ฒ๐ฝ๐ผ๐ฟ๐๐ถ๐ป๐ด ๐๐ถ๐ด๐ป๐ฎ๐น๐, ๐ฑ๐ฒ๐๐ฝ๐ถ๐๐ฒ ๐ป๐ผ๐ ๐ฏ๐ฒ๐ถ๐ป๐ด ๐๐ฝ๐ฒ๐ฐ๐ถ๐ณ๐ถ๐ฐ๐ฎ๐น๐น๐ ๐น๐ถ๐๐๐ฒ๐ฑ ๐ผ๐ป ๐๐ต๐ฒ ๐ฐ๐๐ฟ๐ฟ๐ฒ๐ป๐ ๐ฝ๐ฟ๐ผ๐ฑ๐๐ฐ๐ ๐น๐ฎ๐ฏ๐ฒ๐น. Most reports involved older cats, and while death and euthanasia outcomes were present in the dataset, the authors emphasize that spontaneous reporting systems cannot establish causality.
As with all disproportionality analyses, these findings represent statistical safety signals rather than confirmed adverse drug reactions. Reporting bias, underreporting, incomplete clinical information, and lack of true exposure denominators limit definitive conclusions. The appropriate interpretation is one of measured vigilance โ not alarm โ as post-marketing safety data for anti-NGF monoclonal antibodies continues to evolve
๐ฆ๐ผ๐น๐ฒ๐ป๐๐ถ๐ฎ (๐ณ๐ฟ๐๐ป๐ฒ๐๐ฒ๐๐บ๐ฎ๐ฏ) ๐๐๐๐ฑ๐:
Lai, X., Lin, L., Chen, Y., Wu, L., Huang, Y., & Chen, M. (2026). Safety assessment of frunevetmab for osteoarthritis pain in cats: Disproportionality analysis of the Food and Drug Administration Animal Drug Adverse Events database. Journal of Veterinary Internal Medicine, 40(1), aalag003. https://doi.org/10.1093/jvimsj/aalag003
๐๐ถ๐ฏ๐ฟ๐ฒ๐น๐ฎ (๐ฏ๐ฒ๐ฑ๐ถ๐ป๐๐ฒ๐๐บ๐ฎ๐ฏ) ๐๐๐๐ฑ๐:
Farrell, M., Waibel, F. W. A., Carrera, I., et al. (2025). Musculoskeletal adverse events in dogs receiving bedinvetmab (Librela). Frontiers in Veterinary Science, 12, 1581490. https://pubmed.ncbi.nlm.nih.gov/40417367
